|
 View Archive

Entries for August 2008

Fosamax Adverse Reactions

Fosamax® (alendronate sodium tablets and oral solution) is a bisphosphonate manufactured by Merck, that is marketed, advertised, distributed and sold for the treatment of osteoporosis and Paget’s Disease. It has additionally been prescribed for off label uses such as bone cancers. Fosamax® tablets were approved by the FDA on September 29, 1995, while the oral solution was approved on September 17, 2003.

National Cancer Institute Establishes Web Site to Answer Questions About Malignant Mesothelioma

The National Cancer Institute (NCI) has established a resource on the Internet that provides a direct link to resources available concerning mesothelioma: treatment, prevention, genetics, causes, clinical trials, literature, statistics and research and related information.

US Department of the Interior Reports 36 Locations in NJ with Naturally Occurring Asbestos

The US Geological Survey has reported that NJ ranks 2nd highest in the number of naturally occurring asbestos sites (mines) in the Eastern US.

NY Enacts Legislation Extending 911 Claims Deadline to Sept. 10, 2010

New York State workers’ compensation benefits have been expanded for 911 workers as a result legislation signed Governor Patterson. Under the prior law the registration period would have closed in August 208. The date has been extended to September 10, 2010.

New Chemotherapy Treatment Reported "Responsive" to Mesothelioma

A new set of drugs has been reported responsive in treating mesothelioma, a tumor caused by exposure to asbestos fiber. The British Journal of Cancer has reported that cisplatin and vinorelbine effective in the treatment of mesothelioma.

The Asbestos Debate is Over

Almost 45 years following the historic 1964 NY Academy of Medicine conference in New York experts continue to memorialize the history of asbestos related disease. Now enters, defense expert John E. Craighead, who has written his viewpoint on the subject.
 

Copyright 2019 by Jon Gelman, LLC - Attorney at Law. All rights reserved.   |  Privacy Statement  |  Terms Of Use